Esbriet (pirfenidone) is an anti-fibrotic and anti-inflammatory drug used in the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF). Manufactured by Genentech and given FDA approval in 2014, the drug reduces the amount of lung fibrosis by blocking secretions responsible for excessive collagen production. It also reduces inflammation in the lungs.
7 Common Questions About Esbriet
The anti-inflammatory molecule protectin DX (PDX) has been shown to improve pulmonary fibrosis (PF) and lung function in mice, new research shows. The study, “Posttreatment with Protectin DX ameliorates bleomycin-induced pulmonary fibrosis and lung dysfunction in mice,” was published in the journal Scientific Reports. Lung fibrosis is characterized…
Being diagnosed with a chronic lung disease like pulmonary fibrosis can be overwhelming, and patients often feel isolated and alone. MORE: What you need to know about Esbriet. This was exactly how Debra Baldwin felt after she was diagnosed with pulmonary fibrosis in 2015. According to Fox8, the Burlington,…
Two months ago, I took a bold step to ask for help My husband and I had just returned from a trip to southern California to visit our family. We drove the 800-mile round trip, breaking it up into 200 miles per day because I get so exhausted…
There are many different lung diseases that vary in severity, but one thing is certain: the number of women developing and dying from lung diseases is rapidly rising in the U.S. With early diagnosis comes early treatment which can help prevent the disease from progressing too quickly. Here are some of the most common lung diseases affecting…
Besides its other benefits, Esbriet (pirfenidone) prevents respiratory-related hospitalizations in patients with idiopathic pulmonary fibrosis (IPF), according to a study examining data from more than 1,200 patients. Findings also showed that hospitalized patients who took Esbriet were less likely to die after one year. This effect decreased over time, though researchers…
Proterris and Alfama recently announced a merger of the two companies which will effectively create the world’s leader in the field of carbon monoxide (CO) therapies for acute and chronic diseases, such as pulmonary fibrosis. “The merger of Alfama with Proterris represents a very synergistic and strategic fit between two…
None of us enjoy being in the hospital. However, for a patient with pulmonary fibrosis, it is inevitable that you will have to spend time admitted to the hospital. I find hospital stays very overwhelming. I often feel overly emotional, but do not understand why I shed so…
When people think of wonder drugs they think back to Alexander Fleming’s penicillin, the world’s first antibiotic. They may also think of aspirin, used as a painkiller and also as an anti-clotting agent for patients with a high risk of stroke or heart failure. But there are thousands of drugs that…
Signs are appearing outside restrooms in the United Kingdom to advise members of the public that not all disabilities are visible. MORE: While there is currently no known cure for IPF, there are treatments available to help ease the symptoms. According to a report from the BBC, the…
